Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Prostate-specific antigen Stories

2011-08-15 15:29:51

Novel assay found to be more accurate than traditional screening A new prostate screening test developed by AnalizaDx, Inc., a Cleveland-based biotech company, and studied by researchers at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center along with colleagues at the Cleveland Clinic, the Veterans Administration Boston Healthcare and the National Cancer Institute, may prove to be a promising new tool in the diagnosis of prostate cancer. The study which will be...

2011-08-12 14:52:00

NEW YORK, Aug. 12, 2011 /PRNewswire/ -- Prostate Specific Antigen (PSA) screening is the universal standard for early detection of prostate cancer in men. The medical community, and even the press, routinely urge men to begin PSA testing at age 50, and even earlier - age 40 - for high risk men, including African Americans or those with a family history of prostate cancer. Dr. David Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The...

2011-08-08 12:21:25

A new study supports the use of a DNA-based "biomarker" blood test as a complement to the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. University of Cincinnati (UC) researchers report their findings online ahead of print in the British Journal of Cancer. Researchers conducted a meta-analysis of existing published data related to DNA methylation in bodily fluids. The goal was to evaluate a specific cancer biomarker"”known as GSTP1"”as a...

2011-07-21 08:00:00

CAMBRIDGE, Mass., July 21, 2011 /PRNewswire/ -- Quanterix Corporation, an in-vitro diagnostics (IVD) company providing life science researchers and IVD labs single molecule technology with unprecedented sensitivity and precision, announced that the analytical performance of AccuPSA(TM), a fifth-generation digital immunoassay for Prostate Specific Antigen (PSA), demonstrated a robust 2-log improvement in sensitivity over today's ultrasensitive third-generation assays for measuring PSA in...

2011-07-14 13:07:50

Short-term hormone therapy (androgen deprivation therapy: ADT) given in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in the July 14 issue of the New England Journal of Medicine. This largest randomized trial of its kind enrolled nearly 2,000 men at...

2011-07-13 13:55:27

The widely known PSA blood test for prostate cancer in men may get a second life as a much-needed new test for breast cancer, the most common form of cancer in women worldwide, scientists are reporting in a new study in the ACS journal Analytical Chemistry. Chien Chou and colleagues say that the prostate-specific antigen (PSA) measured in the test also is a potential biomarker of breast cancer in women. However, levels of PSA in healthy women are usually so small that only ultrasensitive...

2011-07-12 12:45:27

Doctors have known for a long time that prostate cancer "runs in the family". Men with relatives who have been diagnosed with prostate cancer have an elevated risk of also developing this type of cancer. It was only last year that DKFZ scientists calculated that this risk rises with the number of affected direct family members and also depends on the relatives' age at outbreak of the disease (DKFZ Press Release 18/2010). The exact DNA variants that contribute to prostate cancer risk have now...

2011-06-15 07:48:00

-20-month extension of the Gen-Probe license- QUEBEC CITY, June 15, 2011 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company commercializing high value cancer diagnostic tests and delivering laboratory services, today reported the issuance of a new U.S. patent, which represents a significant addition to DiagnoCure's PCA3 prostate cancer biomarker portfolio. Moreover, in addition to providing greater patent protection, this new patent bears an extended expiration...

2011-06-10 13:24:02

Receiving radiation therapy immediately after a radical prostatectomy is a cost-effective treatment for prostate cancer patients when compared with waiting and acting on elevated prostate-specific antigen (PSA) levels, according to a new study by researchers at Thomas Jefferson University and Hospital. What's more, a separate, but related study, found that urologists were less likely than radiation oncologists to recommend adjuvant radiation therapy or to believe it improves overall...

2011-06-06 16:42:00

NEW YORK, June 6, 2011 /PRNewswire/ -- According to research presented by Dr. David B. Samadi, a prostate cancer treatment, robotic prostatectomy, and prostate surgery expert, at the annual meeting of the American Urological Association men taking statins, a class of widely used cholesterol-lowering drugs, have significantly lower serum PSA (prostate-specific antigen) levels than their non statin-using counterparts. (Photo: http://photos.prnewswire.com/prnh/20110606/NY14928 ) This PSA...